Lexaria Bioscience Corp. financial metrics

Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q4 2025.

Symbol
LEXX on Nasdaq
Location
Kelowna, British Columbia, Canada
Fiscal year end
31 August
Latest financial report
13 Jan 2026

Latest SEC snapshot (2026-01-13) highlights Return On Equity -155.2%, Return On Assets -83.0%, and Operating Margin -2014.6%.

How Calculated (standard_v1)

Metrics are computed with a market-consensus convention designed for cross-portal comparability.

  • TTM Operating Income / TTM Revenues
  • Current Assets / Current Liabilities (latest instant quarter)
  • (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
  • Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
  • TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
  • TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
  • TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
  • TTM Revenues YoY
  • TTM Net Income YoY

Financial Quality Score

Transparent 0-100 scoring model based on profitability, financial health, and growth factors.

31.8/100

Weak Confidence high

Return On Equity

-155%

Metric score 0.0/100

Return On Assets

-83%

Metric score 0.0/100

Financial Health

Current Ratio
3.68x
Quick Ratio
3.1x
Debt to Equity
0.02x

Strengths

Debt-to-equity

Watchpoints

Return On Equity, Return On Assets, and Operating Margin

Key metrics snapshot

Return On Equity

-155%

YoY: +36%

Industry median: -43% (n=671)

View history

Return On Assets

-83%

YoY: +25%

Industry median: -48% (n=669)

View history

Operating Margin

-2015%

YoY: +40%

Industry median: -128% (n=298)

View history

Current Ratio

3.68x

YoY: -88%

Industry median: 3.39x (n=667)

View history

Quick Ratio

3.1x

YoY: +196%

Industry median: 2.02x (n=287)

View history

Debt-to-equity

0.02x

YoY: +429%

Industry median: 0.28x (n=634)

View history

Revenues YoY

5%

YoY:

Industry median: 5% (n=103)

View history

NetIncomeLoss YoY

-47%

YoY:

Industry median: -0.54% (n=641)

View history

Profitability

Metric Latest value YoY change
Return On Equity -155% +36%
Return On Assets -83% +25%
Operating Margin -2015% +40%

Financial Health

Metric Latest value YoY change
Current Ratio 3.68x -88%
Quick Ratio 3.1x +196%
Debt-to-equity 0.02x +429%

Growth

Metric Latest value YoY change
Revenues YoY 5%
NetIncomeLoss YoY -47%

Share Metrics

Metric Latest value YoY change
Entity Common Stock, Shares Outstanding 24,887,446 +42%
Common Stock, Shares, Outstanding 22,225,846 +27%
Common Stock, Value, Issued $22,226 +27%
Weighted Average Number of Shares Outstanding, Diluted 21,376,029 +28%

Additional Metrics

Metric Latest value YoY change
Research and Development Expense $6,956,877 +86%
General and Administrative Expense $4,328,784 +6.6%
Operating Income (Loss) $10,763,661 -47%
Nonoperating Income (Expense) $36,857 -39%
Income Tax Expense (Benefit) $1,791
Earnings Per Share, Diluted -0.57 -14%
Cash and Cash Equivalents, at Carrying Value $4,300,000
Marketable Securities, Current $0 -100%
Accounts Receivable, after Allowance for Credit Loss, Current $88,044 -67%
Assets, Current $5,363,129 -39%
Property, Plant and Equipment, Net $216,120 -20%
Assets $6,050,807 -38%
Liabilities, Current $1,456,534 +389%
Operating Lease, Liability, Noncurrent $70,819 -31%
Liabilities $1,527,353 +282%
Accumulated Other Comprehensive Income (Loss), Net of Tax $76,079 -231%
Retained Earnings (Accumulated Deficit) $65,055,620 -20%
Stockholders' Equity Attributable to Parent $4,912,892 -50%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $4,523,454 -52%
Liabilities and Equity $6,050,807 -38%
Share-based Payment Arrangement, Noncash Expense $74,895 -25%
Increase (Decrease) in Accounts Receivable $280,314 -357%
Net Cash Provided by (Used in) Operating Activities $984,098 +64%
Net Cash Provided by (Used in) Financing Activities $3,474,051 -20%
Net Cash Provided by (Used in) Investing Activities $5,099 +87%
Common Stock, Shares Authorized 220,000,000 0%
Common Stock, Shares, Issued 22,225,846 +27%
Common Stock, Par or Stated Value Per Share 0.001 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $2,479,110 +57%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $4,281,233 -47%
Operating Lease, Liability $101,920
Payments to Acquire Property, Plant, and Equipment $0 -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $10,846,237 -48%
Operating Lease, Liability, Current $31,101 +7.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two $38,642 +38%
Lessee, Operating Lease, Liability, to be Paid, Year One $28,009
Lessee, Operating Lease, Liability, to be Paid, Year Three $38,900 +4.2%
Lessee, Operating Lease, Liability, to be Paid, Year Four $8,104 -79%
Additional Paid in Capital $70,022,365 +9.3%
Amortization of Intangible Assets $4,857
Depreciation, Depletion and Amortization $12,009 +37%
Share-based Payment Arrangement, Expense $74,895 -25%

How we score

This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.

Metric Weight V1 threshold
ROIC205% to 20%
ROE158% to 25%
ROA102% to 10%
Operating Margin55% to 25%
Current Ratio121.0x to 2.0x
Quick Ratio80.8x to 1.5x
Debt to Equity100.3x to 2.0x (lower is better)
Revenue YoY10-10% to +20%
Net Income YoY10-10% to +20%